Our Pipeline

Antigen
class
HLA type(s) Indication Discovery Candidate Selection Preclinical
/ Scale-up
Clinical
Cell Therapy
Program 1
Tumor
Associated
Antigen
Non-A2
Library
Solid
Tumors
Cell Therapy
Program 2
Novel HLA-A*02:01
or
Non-A2 library
Solid
Tumors

ImmunoScape is building a diverse pipeline of novel TCR-based therapeutics against solid tumors. Our autologous cell therapy programs are directed towards a broad range of shared tumor targets and HLA alleles. Our HLA library consists of highly prevalent HLA alleles (HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-B*07:02) and addresses a large part of the population from North America, Europe and South East Asia. Novel antigen classes include frameshifts, HERVs, indels, neojunctions, and other novel classes of shared antigens.

ImmunoScape’s rapidly evolving TCR portfolio encompasses wholly owned programs and opportunities for external partnering across different types of solid tumors and therapeutic modalities.